Investing.com -- Kala Pharmaceuticals Inc (NASDAQ:KALA) stock dropped 6.7% Friday after the company announced the closing of its previously announced registered direct offering that raised ...
ARLINGTON, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced the closing of its previously announced registered direct offering priced at ...
Securities and Exchange Commission filings indicate that Oxford Finance LLC acquired 1.62 million common shares, representing 16.5% ownership in the clinical-stage company. Oxford Finance, the ...
Investment to support the continued evaluation and redevelopment of KALA’s product candidates and patent portfolio, and provide working capital and funding for a potential future strategic transaction ...
Kala Bio focuses on developing therapies for rare and severe diseases of the eye using its proprietary mesenchymal stem cell secretome platform. Its lead product candidate, KPI-012, had previously ...
ARLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback